Dropropizine    B-Piperazine103946814
(    O
or    O
dipropizine    B-Piperazine103946814
)    O
is    O
a    O
cough    O
suppressant    O
.    O

For    O
example    O
,    O
"    O
DHFR    O
"    O
amplification    O
occurs    O
in    O
response    O
to    O
methotrexate    O
,    O
"    O
TYMS    O
"    O
(    O
involved    O
in    O
DNA    O
synthesis    O
)    O
amplification    O
occurs    O
in    O
response    O
to    O
5-fluorouracil    O
,    O
and    O
"    O
BCR    O
-    O
ABL    O
"    O
amplification    O
occurs    O
in    O
response    O
to    O
imatinib    B-Piperazine103946814
mesylate    I-Piperazine103946814
.    O

Tyrosine    O
kinase    O
inhibitors    O
(    O
such    O
as    O
imatinib    B-Piperazine103946814
and    O
sunitinib    O
)    O
are    O
important    O
drugs    O
against    O
a    O
variety    O
of    O
cancers    O
including    O
CML    O
,    O
renal    O
cell    O
carcinoma    O
(    O
RCC    O
)    O
and    O
gastrointestinal    O
stromal    O
tumors    O
(    O
GISTs    O
)    O
.    O

In    O
the    O
late    O
1990s    O
,    O
STI-571    O
(    O
imatinib    B-Piperazine103946814
,    O
Gleevec    O
/    O
Glivec    O
)    O
was    O
identified    O
by    O
the    O
pharmaceutical    O
company    O
Novartis    O
(    O
then    O
known    O
as    O
Ciba    O
Geigy    O
)    O
in    O
high    O
-    O
throughput    O
screens    O
for    O
tyrosine    O
kinase    O
inhibitors    O
.    O

It    O
was    O
marketed    O
in    O
2001    O
by    O
Novartis    O
as    O
imatinib    B-Piperazine103946814
mesylate    I-Piperazine103946814
(    O
Gleevec    O
in    O
the    O
US    O
,    O
Glivec    O
in    O
Europe    O
)    O
.    O

Imatinib    B-Piperazine103946814
–    O
Anticancer    O
agent    O

Nicholas    O
Lydon    O
(    O
born    O
1957    O
)    O
,    O
awarded    O
the    O
Lasker    O
Clinical    O
Award    O
and    O
Japan    O
Prize    O
for    O
the    O
development    O
of    O
Gleevec    B-Piperazine103946814
.    O

Before    O
the    O
2001    O
U.S.    O
Food    O
and    O
Drug    O
Administration    O
(    O
FDA    O
)    O
approval    O
of    O
imatinib    B-Piperazine103946814
,    O
no    O
drugs    O
were    O
available    O
to    O
alter    O
the    O
natural    O
progression    O
of    O
CML    O
.    O

Imatinib    B-Piperazine103946814
(    O
Gleevec    O
)    O
was    O
discovered    O
in    O
1992    O
and    O
is    O
regarded    O
as    O
first    O
generation    O
drug    O
since    O
it    O
is    O
the    O
first    O
Bcr    O
-    O
Abl    O
tyrosine    O
kinase    O
inhibitor    O
to    O
be    O
used    O
in    O
the    O
treatment    O
of    O
CML    O
.    O

A    O
specialist    O
in    O
chronic    O
myeloid    O
leukaemia    O
,    O
Goldman    O
conducted    O
pioneering    O
research    O
into    O
leukaemia    O
treatment    O
–    O
he    O
was    O
instrumental    O
in    O
the    O
development    O
of    O
bone    O
marrow    O
transplantation    O
as    O
a    O
clinical    O
method    O
,    O
and    O
later    O
in    O
the    O
development    O
of    O
the    O
drug    O
imatinib    B-Piperazine103946814
.    O

From    O
the    O
late    O
1990s    O
onwards    O
,    O
Goldman    O
was    O
instrumental    O
in    O
promoting    O
the    O
use    O
of    O
the    O
anti    O
-    O
cancer    O
drug    O
imatinib    B-Piperazine103946814
,    O
working    O
to    O
refine    O
and    O
expand    O
its    O
clinical    O
usage    O
as    O
a    O
targeted    O
therapy    O
.    O

When    O
modifying    O
the    O
International    O
Nonproprietary    O
Name    O
of    O
a    O
pharmaceutical    O
substance    O
containing    O
the    O
group    O
or    O
anion    O
,    O
the    O
correct    O
spelling    O
is    O
mesilate    O
(    O
as    O
in    O
"    O
imatinib    O
mesilate    O
"    O
,    O
the    O
mesylate    O
salt    O
of    O
imatinib    B-Piperazine103946814
)    O
.    O

As    O
a    O
graduate    O
student    O
working    O
with    O
Nobelist    O
Dr.    O
David    O
Baltimore    O
,    O
Dr.    O
Daley    O
demonstrated    O
that    O
the    O
BCR    O
/    O
ABL    O
oncogene    O
induces    O
chronic    O
myeloid    O
leukemia    O
(    O
CML    O
)    O
in    O
a    O
mouse    O
model    O
,    O
which    O
validated    O
BCR    O
/    O
ABL    O
as    O
a    O
target    O
for    O
drug    O
blockade    O
and    O
encouraged    O
the    O
development    O
of    O
imatinib    B-Piperazine103946814
(    O
Gleevec    O
;    O
Novartis    O
)    O
,    O
a    O
magic    O
-    O
bullet    O
chemotherapy    O
that    O
induces    O
remissions    O
in    O
virtually    O
every    O
CML    O
patient    O
.    O

The    O
activating    O
function    O
of    O
GSAP    O
can    O
be    O
inhibited    O
by    O
the    O
anticancer    O
drug    O
imatinib    B-Piperazine103946814
(    O
Gleevec    O
)    O
which    O
in    O
turn    O
prevents    O
γ-secretase    O
from    O
converting    O
APP    O
into    O
plaque    O
forming    O
β-amyloid    O
without    O
affecting    O
the    O
other    O
functions    O
of    O
γ-secretase    O
.    O

His    O
main    O
scientific    O
contribution    O
relates    O
to    O
the    O
preclinical    O
and    O
clinical    O
development    O
of    O
imatinib    B-Piperazine103946814
.    O

The    O
efficacy    O
of    O
imatinib    B-Piperazine103946814
(    O
trade    O
name    O
Gleevec    O
)    O
,    O
a    O
CD117    O
inhibitor    O
,    O
is    O
determined    O
by    O
the    O
mutation    O
status    O
of    O
CD117    O
:    O

When    O
the    O
mutation    O
has    O
occurred    O
in    O
exon    O
11    O
(    O
as    O
is    O
the    O
case    O
many    O
times    O
in    O
GISTs    O
)    O
,    O
the    O
tumors    O
are    O
responsive    O
to    O
imatinib    B-Piperazine103946814
.    O

However    O
,    O
if    O
the    O
mutation    O
occurs    O
in    O
exon    O
17    O
(    O
as    O
is    O
often    O
the    O
case    O
in    O
seminomas    O
and    O
leukemias    O
)    O
,    O
the    O
receptor    O
is    O
not    O
inhibited    O
by    O
imatinib    B-Piperazine103946814
.    O

Antrafenine    B-Piperazine103946814
(    O
Stakane    B-Piperazine103946814
)    O
is    O
a    O
phenylpiperazine    B-Piperazine103946814
derivative    O
drug    O
invented    O
in    O
1979    O
.    O

Trazodone    O
is    O
a    O
triazolopyridine    O
derivative    O
and    O
a    O
phenylpiperazine    B-Piperazine103946814
that    O
is    O
chemically    O
related    O
to    O
nefazodone    O
and    O
etoperidone    O
,    O
each    O
of    O
which    O
are    O
derivatives    O
of    O
it    O
.    O

S-14,506    B-Piperazine103946814
is    O
a    O
phenylpiperazine    B-Piperazine103946814
,    O
a    O
5-HT1A    O
receptor    O
agonist    O
,    O
and    O
a    O
dopamine    O
receptor    O
antagonist    O
.    O

Eltoprazine    O
(    O
DU-28,853    O
)    O
is    O
a    O
drug    O
of    O
the    O
phenylpiperazine    B-Piperazine103946814
class    O
which    O
is    O
a    O
serenic    O
or    O
antiaggressive    O
agent    O
.    O

Phenylpiperazine    B-Piperazine103946814

Fluprazine    O
(    O
DU-27,716    O
)    O
is    O
a    O
drug    O
of    O
the    O
phenylpiperazine    B-Piperazine103946814
class    O
.    O

Phenylpiperazine    B-Piperazine103946814

MDR    O
-    O
TB    O
can    O
become    O
resistant    O
to    O
the    O
major    O
second    O
-    O
line    O
TB    O
drug    O
groups    O
:    O
fluoroquinolones    O
(    O
moxifloxacin    O
,    O
ofloxacin    B-Piperazine103946814
)    O
and    O
injectable    O
aminoglycoside    O
or    O
polypeptide    O
drugs    O
(    O
amikacin    O
,    O
capreomycin    O
,    O
kanamycin    O
)    O
.    O

ofloxacin    B-Piperazine103946814
(    O
Floxin    O
,    O
Oxaldin    O
,    O
Tarivid    O
)    O

Ofloxacin    B-Piperazine103946814

Induction    O
of    O
matrix    O
metalloproteinase    O
1    O
in    O
rat    O
corneas    O
by    O
ciprofloxacin    O
,    O
ofloxacin    B-Piperazine103946814
and    O
levofloxacin    B-Piperazine103946814
(    O
b    O
,    O
c    O
,    O
d    O
)    O
compared    O
to    O
artificial    O
tears    O
(    O
a    O
)    O
.    O

The    O
molecule    O
was    O
identified    O
by    O
Daiichi    O
Sankyo    O
Co.    O
,    O
which    O
brought    O
ofloxacin    B-Piperazine103946814
and    O
levofloxacin    B-Piperazine103946814
to    O
the    O
market    O
.    O

DBL-583    B-Piperazine103946814
is    O
a    O
selective    O
dopamine    O
reuptake    O
inhibitor    O
of    O
the    O
piperazine    O
chemical    O
class    O
.    O

4-Fluorophenylpiperazine    B-Piperazine103946814
(    O
pFPP    O
)    O

Quipazine    B-Piperazine103946814

Some    O
additional    O
analogues    O
include    O
quipazine    B-Piperazine103946814
,    O
ORG-12962    O
,    O
and    O
3C    O
-    O
PEP    O
.    O

Clorotepine    B-Piperazine103946814

Alnespirone    O
,    O
binospirone    O
,    O
and    O
enilospirone    O
,    O
despite    O
being    O
azapirones    O
,    O
are    O
not    O
piperazines    O
and    O
therefore    O
do    O
not    O
metabolize    O
to    O
1-PP    O
,    O
and    O
while    O
perospirone    B-Piperazine103946814
and    O
tiospirone    B-Piperazine103946814
are    O
piperazines    O
,    O
they    O
are    O
instead    O
benzothiazole    O
-    O
substituted    O
piperazines    O
and    O
do    O
not    O
metabolize    O
to    O
1-PP    O
either    O
.    O

As    O
effective    O
as    O
iloperidone    O
,    O
and    O
13    O
to    O
15%    O
less    O
effective    O
than    O
ziprasidone    B-Piperazine103946814
,    O
chlorpromazine    O
,    O
and    O
asenapine    O
.    O

Lurasidone    O
shows    O
a    O
very    O
close    O
pharmacological    O
profile    O
and    O
has    O
been    O
synthesized    O
similarly    O
to    O
Ziprasidone    B-Piperazine103946814
.    O

Ziprasidone    B-Piperazine103946814
(    O
Partial    O
agonist    O
,    O
Ki    O
=    O
3.4    O
nM    O
)    O

Ziprasidone    B-Piperazine103946814

Ziprasidone    B-Piperazine103946814

Ziprasidone    B-Piperazine103946814

Ziprasidone    B-Piperazine103946814
(    O
Geodon    O
)    O

Some    O
anti    O
-    O
psychotic    O
drugs    O
,    O
such    O
as    O
haloperidol    O
and    O
ziprasidone    B-Piperazine103946814
,    O
have    O
a    O
prolonged    O
QT    O
interval    O
as    O
a    O
rare    O
side    O
-    O
effect    O
.    O

Ziprasidone    B-Piperazine103946814

Ziprasidone    B-Piperazine103946814

Analogues    O
of    O
hydroxyzine    O
include    O
buclizine    B-Piperazine103946814
,    O
cetirizine    O
,    O
cinnarizine    B-Piperazine103946814
,    O
cyclizine    B-Piperazine103946814
,    O
etodroxizine    O
,    O
meclizine    B-Piperazine103946814
,    O
and    O
pipoxizine    O
among    O
others    O
.    O

Buclizine    B-Piperazine103946814
–    O
Antihistamine    O

Sulfoaildenafil    B-Piperazine103946814

LP-44    B-Piperazine103946814
(    O
4-[2-(Methylthio)phenyl]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)-1-piperazinehexanamide    O
)    O

:    O
N05AH06    O
Clotiapine    B-Piperazine103946814

Flibanserin    B-Piperazine103946814

Flibanserin    B-Piperazine103946814

Multifunctional    O
serotonin    O
agonist    O
and    O
antagonist    O
;    O
See    O
Flibanserin    B-Piperazine103946814

Cariprazine    B-Piperazine103946814

Cariprazine    B-Piperazine103946814
,    O
sold    O
under    O
the    O
brand    O
names    O
Vraylar    B-Piperazine103946814
in    O
the    O
United    O
States    O
and    O
Reagila    B-Piperazine103946814
in    O
Europe    O
,    O
is    O
an    O
atypical    O
antipsychotic    O
which    O
is    O
used    O
in    O
the    O
treatment    O
of    O
schizophrenia    O
and    O
bipolar    O
mania    O
.    O

Levofloxacin    B-Piperazine103946814

Induction    O
of    O
matrix    O
metalloproteinase    O
1    O
in    O
rat    O
corneas    O
by    O
ciprofloxacin    O
,    O
ofloxacin    B-Piperazine103946814
and    O
levofloxacin    B-Piperazine103946814
(    O
b    O
,    O
c    O
,    O
d    O
)    O
compared    O
to    O
artificial    O
tears    O
(    O
a    O
)    O
.    O

The    O
molecule    O
was    O
identified    O
by    O
Daiichi    O
Sankyo    O
Co.    O
,    O
which    O
brought    O
ofloxacin    B-Piperazine103946814
and    O
levofloxacin    B-Piperazine103946814
to    O
the    O
market    O
.    O

Ignatova    O
et    O
al    O
.    O
showed    O
that    O
various    O
antibiotics    O
such    O
as    O
tetracycline    O
hydrochloride    O
,    O
ciprofloxacin    O
and    O
levofloxacin    B-Piperazine103946814
can    O
be    O
incorporated    O
into    O
the    O
synthetic    O
polymer    O
solution    O
that    O
can    O
be    O
electrospun    O
to    O
produce    O
fibers    O
that    O
can    O
be    O
delivered    O
to    O
the    O
site    O
of    O
interest    O
.    O

Alternatively    O
,    O
a    O
single    O
dose    O
azithromycin    O
or    O
levofloxacin    B-Piperazine103946814
may    O
be    O
prescribed    O
.    O

Levofloxacin    B-Piperazine103946814

Antibiotics    O
are    O
typically    O
given    O
for    O
three    O
to    O
five    O
days    O
,    O
but    O
single    O
doses    O
of    O
azithromycin    O
or    O
levofloxacin    B-Piperazine103946814
have    O
been    O
used    O
.    O

Treatment    O
of    O
osteomyelitis    O
,    O
in    O
this    O
case    O
,    O
will    O
be    O
to    O
use    O
fluoroquinolones    O
(    O
ciprofloxacin    O
,    O
levofloxacin    B-Piperazine103946814
,    O
etc    O
.    O
,    O
and    O
nalidixic    O
acid    O
)    O
.    O

Maxaquin    B-Piperazine103946814

Orbifloxacin    B-Piperazine103946814
(    O
brand    O
name    O
Orbax    B-Piperazine103946814
)    O
is    O
a    O
fluoroquinolone    O
antibiotic    O
which    O
is    O
approved    O
for    O
use    O
in    O
dogs    O
,    O
marketed    O
by    O
Schering    O
-    O
Plough    O
Animal    O
Health    O
.    O

Almitrine    B-Piperazine103946814
(    O
marketed    O
as    O
Duxil    B-Piperazine103946814
by    O
Servier    O
)    O
is    O
a    O
diphenylmethylpiperazine    B-Piperazine103946814
derivative    O
classified    O
as    O
a    O
respiratory    O
stimulant    O
by    O
the    O
ATC    O
.    O

:    O
N05AB08    O
Thioproperazine    B-Piperazine103946814

It    O
is    O
derived    O
from    O
cyclohexylpiperazine    B-Piperazine103946814
.    O

Adatanserin    B-Piperazine103946814

Casopitant    B-Piperazine103946814

Casopitant    B-Piperazine103946814
(    O
INN    O
,    O
tentative    O
trade    O
names    O
Rezonic    B-Piperazine103946814
(    O
U.S.    O
)    O
,    O
Zunrisa    B-Piperazine103946814
(    O
Europe    O
)    O
)    O
is    O
an    O
neurokinin    O
1    O
receptor    O
(    O
NK1R    O
)    O
antagonist    O
undergoing    O
research    O
for    O
the    O
treatment    O
of    O
chemotherapy    O
-    O
induced    O
nausea    O
and    O
vomiting    O
(    O
CINV    O
)    O
.    O

DPI-221    B-Piperazine103946814

AD-1211    B-Piperazine103946814

AD-1211    B-Piperazine103946814

CGS-12066A    B-Piperazine103946814

Model    O
of    O
the    O
inhibitor    O
olaparib    B-Piperazine103946814
(    O
dark    O
gray    O
)    O
occupying    O
the    O
NAD+-binding    O
site    O
of    O
PARP1    O
.    O

Olaparib    B-Piperazine103946814
,    O
a    O
PARP1    O
inhibitor    O
,    O
shrunk    O
or    O
stopped    O
the    O
growth    O
of    O
tumors    O
from    O
breast    O
,    O
ovarian    O
and    O
prostate    O
cancers    O
caused    O
by    O
mutations    O
in    O
the    O
BRCA1    O
or    O
BRCA2    O
genes    O
,    O
which    O
are    O
necessary    O
for    O
HR    O
.    O

Talazoparib    O
is    O
similar    O
to    O
the    O
first    O
in    O
class    O
PARP    O
inhibitor    O
,    O
olaparib    B-Piperazine103946814
.    O

Balofloxacin    B-Piperazine103946814
is    O
an    O
orally    O
active    O
fluoroquinolone    O
antibiotic    O
developed    O
by    O
Choongwae    O
Pharma    O
for    O
the    O
treatment    O
of    O
urinary    O
tract    O
infections    O
.    O

The    O
triazole    O
antifungal    O
drugs    O
include    O
fluconazole    O
,    O
isavuconazole    O
,    O
itraconazole    O
,    O
voriconazole    O
,    O
pramiconazole    B-Piperazine103946814
,    O
ravuconazole    O
,    O
and    O
posaconazole    O
.    O

SRT1460    B-Piperazine103946814

Rimcazole    B-Piperazine103946814
is    O
an    O
antagonist    O
of    O
the    O
sigma    O
receptor    O
as    O
well    O
as    O
a    O
dopamine    O
reuptake    O
inhibitor    O
.    O

Praziquantel    B-Piperazine103946814

A    O
"    O
P.    O
kellicottii    O
"    O
treatment    O
in    O
humans    O
consists    O
oral    O
medication    O
of    O
praziquantel    B-Piperazine103946814
over    O
a    O
minimum    O
of    O
three    O
days    O
to    O
achieve    O
a    O
100%    O
cure    O
rate    O
when    O
the    O
parasite    O
is    O
located    O
in    O
the    O
lungs    O
.    O

A    O
case    O
of    O
the    O
Mazzotti    O
reaction    O
has    O
been    O
reported    O
after    O
presumptive    O
treatment    O
of    O
schistosomiasis    O
and    O
strongyloidiasis    O
with    O
ivermectin    O
,    O
praziquantel    B-Piperazine103946814
and    O
albendazole    O
.    O

The    O
two    O
drugs    O
that    O
have    O
been    O
well    O
-    O
described    O
for    O
the    O
treatment    O
of    O
hymenolepiasis    O
are    O
praziquantel    B-Piperazine103946814
and    O
niclosamide    O
.    O

Praziquantel    B-Piperazine103946814
is    O
not    O
effective    O
,    O
and    O
older    O
drugs    O
such    O
as    O
bithionol    O
are    O
moderately    O
effective    O
but    O
also    O
cause    O
more    O
side    O
effects    O
.    O

Praziquantel    B-Piperazine103946814
treatment    O
is    O
ineffective    O
.    O

Praziquantel    B-Piperazine103946814
is    O
the    O
drug    O
of    O
choice    O
for    O
treatment    O
.    O

"    O
Gyrodactylus    O
"    O
infections    O
in    O
fish    O
tanks    O
can    O
be    O
treated    O
using    O
a    O
combination    O
of    O
formalin    O
,    O
trichlorfon    O
and    O
praziquantel    B-Piperazine103946814
for    O
a    O
minimum    O
of    O
17    O
days    O
with    O
none    O
/    O
little    O
risk    O
for    O
Bay    O
pipefish    O
mortality    O
.    O

Praziquantel    B-Piperazine103946814
(    O
for    O
tapeworm    O
infections    O
)    O

Praziquantel    B-Piperazine103946814

Other    O
drugs    O
such    O
as    O
ivermectin    O
and    O
praziquantel    B-Piperazine103946814
have    O
been    O
tried    O
,    O
but    O
are    O
neither    O
reliable    O
nor    O
rapidly    O
effective    O
.    O

Praziquantel    B-Piperazine103946814
is    O
effective    O
against    O
various    O
helminthic    O
and    O
protozoan    O
infections    O
.    O

sarafloxacin    B-Piperazine103946814
(    O
Floxasol    O
,    O
Saraflox    O
,    O
Sarafin    O
)    O
(    O
for    O
veterinary    O
use    O
)    O

S-14,506    B-Piperazine103946814
is    O
a    O
phenylpiperazine    B-Piperazine103946814
,    O
a    O
5-HT1A    O
receptor    O
agonist    O
,    O
and    O
a    O
dopamine    O
receptor    O
antagonist    O
.    O

Ipsapirone    B-Piperazine103946814
-    O
anxiolytic    O

Naluzotan    B-Piperazine103946814
—    O
antidepressant    O

Picloxydine    B-Piperazine103946814
(    O
trade    O
name    O
Vitabact    B-Piperazine103946814
)    O
is    O
a    O
bisbiguanide    O
antiseptic    O
used    O
in    O
eye    O
drops    O
.    O

:    O
N05AF02    O
Clopenthixol    B-Piperazine103946814

It    O
is    O
the    O
"    O
cis    O
"-    O
isomer    O
of    O
clopenthixol    B-Piperazine103946814
(    O
Sordinol    O
,    O
Ciatyl    O
)    O
.    O

Revospirone    B-Piperazine103946814
-    O
anxiolytic    O

Perathiepin    B-Piperazine103946814

Acaprazine    B-Piperazine103946814
—    O
anxiolytic    O

:    O
N05AX16    O
Brexpiprazole    B-Piperazine103946814

Brexpiprazole    B-Piperazine103946814

Moreover    O
,    O
flunarizine    B-Piperazine103946814
is    O
another    O
calcium    O
antagonist    O
which    O
is    O
used    O
to    O
treat    O
migraines    O
.    O

Examples    O
of    O
drugs    O
commonly    O
associated    O
with    O
depressogenic    O
effects    O
include    O
some    O
anticonvulsants    O
such    O
as    O
the    O
barbiturates    O
(    O
e.g.    O
phenobarbital    O
)    O
,    O
benzodiazepines    O
(    O
e.g.    O
diazepam    O
)    O
,    O
vigabatrin    O
,    O
and    O
topiramate    O
,    O
corticosteroids    O
like    O
dexamethasone    O
and    O
prednisone    O
,    O
cytokines    O
like    O
interferon-α    O
and    O
interleukin-2    O
,    O
certain    O
antihypertensives    O
such    O
as    O
amiodarone    O
,    O
clonidine    O
,    O
methyldopa    O
,    O
reserpine    O
,    O
and    O
tetrabenazine    O
(    O
used    O
as    O
an    O
antipsychotic    O
/    O
antihyperkinetic    O
)    O
,    O
and    O
agents    O
with    O
antiandrogen    O
,    O
antiestrogen    O
,    O
and/or    O
anti    O
-    O
neurosteroid    O
activities    O
such    O
as    O
GnRH    O
agonists    O
(    O
e.g.    O
,    O
leuprolide    O
,    O
goserelin    O
)    O
,    O
anastrozole    O
(    O
an    O
aromatase    O
inhibitor    O
)    O
,    O
finasteride    O
(    O
a    O
5α-reductase    O
inhibitor    O
)    O
,    O
and    O
clomiphene    O
(    O
a    O
SERM    O
)    O
,    O
as    O
well    O
as    O
others    O
including    O
flunarizine    B-Piperazine103946814
,    O
mefloquine    O
,    O
and    O
efavirenz    O
.    O

4-Methoxyphenylpiperazine    B-Piperazine103946814
(    O
MeOPP    O
)    O

gatifloxacin    B-Piperazine103946814
(    O
Zigat    O
,    O
Tequin    O
)    O
(    O
Zymar    O
-opth    O
.    O
)    O

gatifloxacin    B-Piperazine103946814
(    O
INN    O
)    O

Mirtazapine    B-Piperazine103946814
(    O
Remeron    O
)    O
,    O
NaSSA    O

It    O
is    O
not    O
uncommon    O
for    O
SSRIs    O
to    O
cause    O
or    O
worsen    O
insomnia    O
;    O
the    O
sedating    O
noradrenergic    O
and    O
specific    O
serotonergic    O
antidepressant    O
(    O
NaSSA    O
)    O
antidepressant    O
mirtazapine    B-Piperazine103946814
(    O
Zispin    O
,    O
Remeron    O
)    O
can    O
be    O
used    O
in    O
such    O
cases    O
.    O

He    O
was    O
prescribed    O
the    O
antidepressants    O
Zoloft    O
and    O
later    O
Avanza    B-Piperazine103946814
.    O

Hence    O
,    O
trazodone    O
does    O
not    O
have    O
similar    O
properties    O
to    O
selective    O
serotonin    O
reuptake    O
inhibitors    O
(    O
SSRIs    O
)    O
and    O
is    O
not    O
particularly    O
associated    O
with    O
increased    O
appetite    O
and    O
weight    O
gain    O
,    O
unlike    O
other    O
5-HT2C    O
antagonists    O
like    O
mirtazapine    B-Piperazine103946814
.    O

In    O
contrast    O
to    O
older    O
sedating    O
drugs    O
acting    O
on    O
5-HT2A    O
receptors    O
(    O
e.g.    O
,    O
mirtazapine    B-Piperazine103946814
,    O
clozapine    O
,    O
risperidone    O
)    O
,    O
eplivanserin    O
has    O
practically    O
no    O
affinity    O
to    O
dopamine    O
,    O
histamine    O
and    O
adrenergic    O
receptors    O
.    O

Mirtazapine    B-Piperazine103946814
,    O
sold    O
under    O
the    O
brand    O
name    O
Remeron    B-Piperazine103946814
among    O
others    O
,    O
is    O
an    O
atypical    O
antidepressant    O
which    O
is    O
used    O
primarily    O
in    O
the    O
treatment    O
of    O
depression    O
.    O

On    O
the    O
psychiatric    O
front    O
researchers    O
at    O
Newhouse    O
supported    O
the    O
development    O
of    O
mirtazepine    B-Piperazine103946814
,    O
a    O
novel    O
tetracyclic    O
anti    O
-    O
depressant    O
which    O
has    O
become    O
widely    O
prescribed    O
throughout    O
the    O
world    O
.    O

Commonly    O
used    O
ones    O
are    O
venlafaxine    O
,    O
nefazadone    O
,    O
bupropion    O
,    O
mirtazapine    B-Piperazine103946814
and    O
trazodone    O
.    O

In    O
level    O
three    O
,    O
patients    O
were    O
offered    O
the    O
addition    O
of    O
lithium    O
or    O
triiodothyronine    O
(    O
a    O
thyroid    O
hormone    O
)    O
to    O
their    O
antidepressant    O
,    O
or    O
a    O
switch    O
to    O
another    O
antidepressant    O
(    O
mirtazapine    B-Piperazine103946814
or    O
nortriptyline    O
)    O
.    O

Level    O
four    O
consisted    O
of    O
the    O
monoamine    O
oxidase    O
inhibitor    O
tranylcypromine    O
or    O
a    O
combination    O
of    O
venlafaxine    O
and    O
mirtazapine    B-Piperazine103946814
.    O

Mirtazapine    B-Piperazine103946814

California    B-Piperazine103946814
rocket    I-Piperazine103946814
fuel    I-Piperazine103946814

Suproclone    O
is    O
very    O
similar    O
in    O
structure    O
to    O
the    O
related    O
drug    O
suriclone    B-Piperazine103946814
,    O
but    O
little    O
information    O
has    O
been    O
published    O
about    O
it    O
specifically    O
.    O

Other    O
agents    O
which    O
have    O
been    O
shown    O
to    O
reverse    O
chloroquine    O
resistance    O
in    O
malaria    O
are    O
chlorpheniramine    O
,    O
gefitinib    O
,    O
imatinib    B-Piperazine103946814
,    O
tariquidar    O
and    O
zosuquidar    B-Piperazine103946814
.    O

:    O
N05AB10    O
Perazine    B-Piperazine103946814

enoxacin    B-Piperazine103946814
(    O
INN    O
)    O

2,3-Dichlorophenylpiperazine    B-Piperazine103946814
,    O
a    O
chemical    O
compound    O

:    O
QN05AD90    O
Azaperone    B-Piperazine103946814

Desmethylclozapine    B-Piperazine103946814

Benztropine    O
,    O
mazindol    O
,    O
and    O
vanoxerine    B-Piperazine103946814
also    O
bind    O
to    O
these    O
sites    O
and    O
have    O
similar    O
properties    O
.    O

It    O
is    O
the    O
decanoate    O
ester    O
of    O
a    O
hydroxy    O
vanoxerine    B-Piperazine103946814
.    O

Combined    O
with    O
marbofloxacin    B-Piperazine103946814
and    O
clotrimazole    O
,    O
dexamethasone    O
is    O
available    O
under    O
the    O
name    O
Aurizon    O
,    O
CAS    O
number    O
115550    O
-    O
35    O
-    O
1    O
,    O
and    O
used    O
to    O
treat    O
difficult    O
ear    O
infections    O
,    O
especially    O
in    O
dogs    O
.    O

MT-45    B-Piperazine103946814

MT-45    B-Piperazine103946814

Analogues    O
of    O
hydroxyzine    O
include    O
buclizine    B-Piperazine103946814
,    O
cetirizine    O
,    O
cinnarizine    B-Piperazine103946814
,    O
cyclizine    B-Piperazine103946814
,    O
etodroxizine    O
,    O
meclizine    B-Piperazine103946814
,    O
and    O
pipoxizine    O
among    O
others    O
.    O

Cinnarizine    B-Piperazine103946814

loprazolam    B-Piperazine103946814

Benzodiazepines    O
with    O
a    O
half    O
-    O
life    O
of    O
less    O
than    O
24    O
hours    O
include    O
alprazolam    O
,    O
bromazepam    O
,    O
brotizolam    O
,    O
flunitrazepam    O
,    O
loprazolam    B-Piperazine103946814
,    O
lorazepam    O
,    O
lormetazepam    O
,    O
midazolam    O
,    O
nitrazepam    O
,    O
oxazepam    O
,    O
and    O
temazepam    O
.    O

It    O
is    O
closely    O
related    O
to    O
several    O
other    O
piperazines    O
,    O
including    O
eltoprazine    O
and    O
batoprazine    B-Piperazine103946814
,    O
and    O
TFMPP    B-Piperazine103946814
,    O
as    O
well    O
as    O
more    O
distantly    O
to    O
the    O
azapirones    O
such    O
as    O
buspirone    O
.    O

SB-357,134    B-Piperazine103946814

Aminoethylpiperazine    B-Piperazine103946814

Pitrazepin    B-Piperazine103946814

Gepirone    B-Piperazine103946814
is    O
an    O
antidepressant    O
and    O
anxiolytic    O
drug    O
of    O
the    O
azapirone    O
group    O
that    O
was    O
synthesized    O
by    O
Bristol    O
-    O
Myers    O
Squibb    O
in    O
1986    O
and    O
has    O
been    O
under    O
development    O
for    O
the    O
treatment    O
of    O
depression    O
but    O
has    O
yet    O
to    O
be    O
marketed    O
.    O

It    O
has    O
been    O
under    O
development    O
in    O
the    O
U.S.    O
in    O
an    O
extended    O
release    O
form    O
(    O
referred    O
to    O
as    O
gepirone    B-Piperazine103946814
ER    I-Piperazine103946814
)    O
,    O
but    O
despite    O
completing    O
phase    O
III    O
clinical    O
trials    O
and    O
demonstrating    O
efficacy    O
,    O
it    O
has    O
been    O
rejected    O
multiple    O
times    O
by    O
the    O
Food    O
and    O
Drug    O
Administration    O
(    O
FDA    O
)    O
during    O
the    O
drug    O
approval    O
process    O
.    O

Tolpiprazole    B-Piperazine103946814
(    O
tranquilizer    O
)    O

All    O
diphenylmethylpiperazine    B-Piperazine103946814
are    O
also    O
technically    O
benzylpiperazines    O
.    O

Diphenylmethylpiperazine    B-Piperazine103946814

Diphenylmethylpiperazine    B-Piperazine103946814

Benzylpiperazine    B-Piperazine103946814
,    O
a    O
recreational    O
drug    O

1-Benzylpiperazine    B-Piperazine103946814
(    O
BZP    O
)    O

mCPP    O
is    O
not    O
scheduled    O
at    O
the    O
federal    O
level    O
in    O
the    O
United    O
States    O
,    O
but    O
it    O
is    O
possible    O
that    O
it    O
could    O
be    O
considered    O
a    O
controlled    O
substance    O
analog    O
of    O
BZP    B-Piperazine103946814
,    O
in    O
which    O
case    O
purchase    O
,    O
sale    O
,    O
or    O
possession    O
could    O
be    O
prosecuted    O
under    O
the    O
Federal    O
Analog    O
Act    O
.    O

Jacqui    O
Dean    O
campaigned    O
for    O
the    O
banning    O
of    O
the    O
sale    O
of    O
"    O
party    O
pills    O
"    O
,    O
namely    O
Benzylpiperazine    B-Piperazine103946814
(    O
BZP    O
)    O
,    O
over    O
which    O
Associate    O
Health    O
Minister    O
Jim    O
Anderton    O
(    O
Progressive    O
party    O
)    O
has    O
accused    O
her    O
of    O
indulging    O
in    O
political    O
grandstanding    O
,    O
saying    O
–    O
"    O
'    O
'    O
Perhaps    O
Mrs    O
Dean    O
does    O
n't    O
subscribe    O
to    O
the    O
idea    O
that    O
any    O
Government    O
must    O
balance    O
the    O
need    O
to    O
act    O
promptly    O
with    O
its    O
responsibilities    O
to    O
act    O
fairly    O
and    O
follow    O
due    O
process    O
,    O
particularly    O
where    O
its    O
actions    O
affect    O
those    O
who    O
are    O
currently    O
acting    O
within    O
existing    O
legal    O
constraints    O
.    O
''    O
"    O
Dean    O
's    O
press    O
releases    O
refer    O
to    O
BZP    O
as    O
either    O
"    O
cattle    O
drench    O
"    O
or    O
a    O
"    O
worming    O
agent    O
"    O
.    O

Following    O
a    O
friend    O
's    O
death    O
,    O
Bowden    O
contracted    O
a    O
research    O
team    O
to    O
identify    O
safer    O
alternatives    O
to    O
illicit    O
substances    O
and    O
identified    O
benzylpiperazine    B-Piperazine103946814
from    O
research    O
and    O
began    O
dialogue    O
with    O
New    O
Zealand    O
's    O
Ministry    O
of    O
Health    O
Drug    O
Policy    O
Team    O
,    O
identifying    O
himself    O
as    O
a    O
community    O
member    O
with    O
a    O
potential    O
solution    O
for    O
drug    O
demand    O
reduction    O
as    O
called    O
for    O
in    O
methamphetamine    O
action    O
plan    O
.    O

benzylpiperazine    B-Piperazine103946814
(    O
BZP    O
)    O

Benzylpiperazine    B-Piperazine103946814

As    O
with    O
UK    O
based    O
head    O
shops    O
,    O
both    O
paraphernalia    O
and    O
"    O
legal    O
highs    O
"    O
are    O
available    O
from    O
these    O
stores    O
,    O
such    O
as    O
Salvia    O
Divinorum    O
and    O
BZP    B-Piperazine103946814
based    O
products    O
designed    O
to    O
simulate    O
illegal    O
drug    O
highs    O
such    O
as    O
those    O
experienced    O
through    O
the    O
use    O
of    O
amphetamine    O
[    O
speed    O
]    O
,    O
methamphetamine    O
,    O
and    O
psychedelics    O
[    O
psilocybin    O
]    O
.    O

6-Nitroquipazine    B-Piperazine103946814

Dapiprazole    B-Piperazine103946814
(    O
Rev-Eyes    B-Piperazine103946814
)    O
is    O
an    O
alpha    O
blocker    O
.    O

"    O
S.    O
xylosus    O
"    O
is    O
normally    O
sensitive    O
to    O
fleroxacin    B-Piperazine103946814
,    O
methicillin    O
,    O
penicillin    O
,    O
teicoplanin    O
,    O
erythromycin    O
and    O
tetracycline    O
,    O
and    O
resistant    O
to    O
novobiocin    O
.    O

PD-168,077    B-Piperazine103946814

Fluperlapine    B-Piperazine103946814

lidoflazine    B-Piperazine103946814
(    O
INN    O
)    O

Zolertine    B-Piperazine103946814
—    O
antihypertensive    O

BD1063    B-Piperazine103946814
or    O
1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine    O
is    O
a    O
selective    O
sigma    O
receptor    O
antagonist    O
,    O
with    O
a    O
reported    O
binding    O
affinity    O
of    O
"    O
K"i    O
=    O
9    O
±    O
1    O
nM    O
for    O
the    O
sigma-1    O
receptor    O
and    O
more    O
than    O
49    O
times    O
selectivity    O
over    O
the    O
sigma-2    O
receptor    O
.    O

Lurasidone    B-Piperazine103946814
(    O
trade    O
name    O
Latuda    B-Piperazine103946814
)    O
is    O
an    O
atypical    O
antipsychotic    O
developed    O
by    O
Dainippon    O
Sumitomo    O
Pharma    O
and    O
marketed    O
by    O
Sunovion    O
in    O
the    O
U.S.    O

Lurasidone    B-Piperazine103946814
(    O
Latuda    O
)    O

Lurasidone    B-Piperazine103946814

Lurasidone    B-Piperazine103946814

Lurasidone    O
is    O
chemically    O
similar    O
to    O
Perospirone    B-Piperazine103946814
(    O
also    O
a    O
chemical    O
analogue    O
of    O
Zeldox    O
)    O
,    O
as    O
well    O
as    O
Risperidone    O
,    O
Paliperidone    O
and    O
Iloperidone    O
.    O

Alnespirone    O
,    O
binospirone    O
,    O
and    O
enilospirone    O
,    O
despite    O
being    O
azapirones    O
,    O
are    O
not    O
piperazines    O
and    O
therefore    O
do    O
not    O
metabolize    O
to    O
1-PP    O
,    O
and    O
while    O
perospirone    B-Piperazine103946814
and    O
tiospirone    B-Piperazine103946814
are    O
piperazines    O
,    O
they    O
are    O
instead    O
benzothiazole    O
-    O
substituted    O
piperazines    O
and    O
do    O
not    O
metabolize    O
to    O
1-PP    O
either    O
.    O

NGD-4715    B-Piperazine103946814

azimilide    B-Piperazine103946814
(    O
INN    O
)    O

ensaculin    B-Piperazine103946814
(    O
INN    O
)    O

Amoxapine    B-Piperazine103946814

Along    O
with    O
trimipramine    O
,    O
iprindole    O
,    O
and    O
amoxapine    B-Piperazine103946814
,    O
it    O
has    O
been    O
described    O
as    O
an    O
"    O
atypical    O
"    O
or    O
"    O
second    O
-    O
generation    O
"    O
TCA    O
due    O
to    O
its    O
relatively    O
late    O
introduction    O
and    O
atypical    O
pharmacology    O
.    O

Nortriptyline    O
,    O
desipramine    O
,    O
and    O
amoxapine    B-Piperazine103946814
are    O
tricyclic    O
antidepressants    O
and    O
secondary    O
amines    O
.    O

Amoxapine    B-Piperazine103946814

Structurally    O
related    O
first    O
generation    O
drugs    O
,    O
but    O
formally    O
not    O
4-quinolones    O
,    O
include    O
cinoxacin    O
(    O
Cinobac    O
)    O
,    O
nalidixic    O
acid    O
(    O
NegGam    O
,    O
Wintomylon    O
)    O
,    O
and    O
piromidic    O
acid    O
(    O
Panacid    O
)    O
,    O
pipemidic    B-Piperazine103946814
acid    I-Piperazine103946814
(    O
Dolcol    O
)    O

Ceftiolene    B-Piperazine103946814
(    O
INN    O
)    O
is    O
a    O
third    O
-    O
generation    O
cephalosporin    O
antibiotic    O
.    O

lorpiprazole    B-Piperazine103946814
(    O
INN    O
)    O

For    O
people    O
with    O
motion    O
sickness    O
and    O
vertigo    O
,    O
antihistamines    O
and    O
anticholinergics    O
such    O
as    O
meclizine    B-Piperazine103946814
and    O
scopolamine    O
are    O
particularly    O
effective    O
.    O

Visitors    O
also    O
appreciated    O
what    O
was    O
only    O
loosely    O
connected    O
with    O
the    O
scientific    O
sessions    O
,    O
in    O
1970    O
when    O
″people    O
in    O
Porto    O
still    O
understood    O
by    O
a    O
coffee    O
break    O
a    O
port    O
break″    O
,    O
in    O
1973    O
″Serafim    O
Guimarães    O
'    O
Coimbra    O
fados    O
,    O
the    O
fabulous    O
dinner    O
given    O
by    O
the    O
mayor    O
of    O
Amarante″    O
,    O
in    O
1989    O
″the    O
unanimous    O
wish    O
for    O
scopolamine    O
oder    O
meclizine    B-Piperazine103946814
on    O
the    O
Douro    O
valley    O
serpentine    O
tour    O
.    O
“    O

meclozine    B-Piperazine103946814

The    O
treatments    O
for    O
significant    O
retching    O
include    O
correction    O
of    O
fluid    O
and    O
electrolyte    O
balance    O
,    O
nutritional    O
support    O
and    O
medications    O
like    O
phenothiazines    O
(    O
such    O
as    O
Compazine    O
and    O
Phenergan    O
)    O
,    O
5-HT3    O
antagonist    O
(    O
such    O
as    O
Zofran    O
)    O
,    O
dopamine    O
receptor    O
antagonists    O
(    O
such    O
as    O
Reglan    O
)    O
,    O
antihistamines    O
(    O
Antivert    B-Piperazine103946814
,    O
and    O
Dramamine    O
,    O
Benadryl    O
)    O
and    O
anticholinergics    O
(    O
Scopolamine    O
)    O
.    O

Pipofezine    B-Piperazine103946814
(    O
Azafen    O
/    O
Azaphen    O
)    O

The    O
Virginia    O
Cooperative    O
Extension    O
recommends    O
Micotil    O
,    O
Nuflor    O
,    O
and    O
Baytril    B-Piperazine103946814
100    I-Piperazine103946814
as    O
newer    O
antibiotics    O
that    O
do    O
not    O
need    O
daily    O
dosing    O
,    O
but    O
also    O
notes    O
that    O
Naxcel    O
,    O
Excenel    O
,    O
and    O
Adspec    O
are    O
effective    O
as    O
well    O
.    O

In    O
1998    O
and    O
1999    O
,    O
Chopra    O
,    O
along    O
with    O
two    O
co    O
-    O
workers    O
,    O
Drs    O
.    O
Margaret    O
Haydon    O
and    O
Gerard    O
Lambert    O
,    O
testified    O
to    O
the    O
Canadian    O
Senate    O
"    O
Standing    O
Committee    O
on    O
Agriculture    O
and    O
Forestry    O
"    O
that    O
they    O
were    O
pressured    O
by    O
senior    O
supervisors    O
to    O
approve    O
multiple    O
drugs    O
of    O
questionable    O
safety    O
,    O
including    O
Bovine    O
Growth    O
Hormone    O
(    O
rBST    O
)    O
and    O
Baytril    B-Piperazine103946814
,    O
which    O
in    O
the    O
words    O
of    O
Chopra    O
,    O
"    O
is    O
even    O
more    O
controversial    O
.    O

Following    O
this    O
,    O
Chopra    O
,    O
Haydon    O
,    O
Lambert    O
and    O
colleague    O
Chris    O
Bassude    O
complained    O
to    O
the    O
Public    O
Service    O
Integrity    O
Officer    O
(    O
PSIO    O
)    O
office    O
,    O
a    O
federal    O
investigative    O
body    O
under    O
the    O
jurisdiction    O
of    O
the    O
Treasury    O
Board    O
of    O
Canada    O
,    O
indicating    O
again    O
that    O
they    O
were    O
pressured    O
by    O
their    O
seniors    O
to    O
pass    O
a    O
number    O
of    O
veterinary    O
drugs    O
,    O
including    O
Tylosin    O
,    O
Revalor    O
H    O
,    O
Synergistin    O
Injectable    O
Suspension    O
,    O
Baytril    B-Piperazine103946814
,    O
rBST    O
,    O
Carbodex    O
and    O
Eugenol    O
,    O
without    O
proof    O
of    O
human    O
safety    O
.    O

NAN-190    B-Piperazine103946814

Sigma    O
-    O
Tau    O
in    O
collaboration    O
with    O
the    O
non    O
-    O
profit    O
organization    O
Medicines    O
for    O
Malaria    O
Venture    O
(    O
MMV    O
)    O
has    O
developed    O
a    O
new    O
medicine    O
for    O
the    O
treatment    O
of    O
malaria    O
a    O
fixed    O
combination    O
consisting    O
of    O
dihydroartemisinin    O
and    O
piperaquine    B-Piperazine103946814
,    O
judged    O
to    O
be    O
one    O
of    O
the    O
most    O
effective    O
antimalaria    O
medicines    O
available    O
and    O
the    O
best    O
combination    O
containing    O
artemisinin    O
.    O

collaborates    O
with    O
Medicines    O
for    O
Malaria    O
Venture    O
(    O
MMV    O
)    O
)    O
,    O
an    O
association    O
supported    O
by    O
the    O
Bill    O
&    O
Melinda    O
Gates    O
Foundation    O
in    O
the    O
development    O
of    O
one    O
of    O
the    O
most    O
efficient    O
antimalaria    O
medicines    O
available    O
,    O
a    O
fixed    O
combination    O
consisting    O
of    O
dihydroartemisinin    O
and    O
piperaquine    B-Piperazine103946814
judged    O
to    O
be    O
the    O
best    O
combination    O
containing    O
artemisinin    O
,    O
partly    O
due    O
to    O
the    O
low    O
incidence    O
of    O
side    O
effects    O
;    O

There    O
is    O
tentative    O
evidence    O
for    O
the    O
medication    O
flupentixol    B-Piperazine103946814
;    O
however    O
,    O
greater    O
study    O
is    O
required    O
before    O
it    O
can    O
be    O
recommended    O
.    O

Between    O
March    O
and    O
April    O
1991    O
,    O
Charnley    O
experimented    O
with    O
varying    O
dosages    O
of    O
his    O
medication    O
-    O
Depixol    B-Piperazine103946814
and    O
Tryptisol    O
-    O
painting    O
a    O
self    O
-    O
portrait    O
each    O
day    O
that    O
reflected    O
how    O
his    O
concept    O
of    O
'    O
self    O
'    O
changed    O
with    O
the    O
illness    O
.    O

Flupenthixol    B-Piperazine103946814
(    O
Fluanxol    O
)    O

Some    O
other    O
cyclopyrrolone    O
drugs    O
include    O
zopiclone    B-Piperazine103946814
and    O
eszopiclone    B-Piperazine103946814
.    O

Her    O
advertising    O
credits    O
include    O
McDonald    O
's    O
jingles    O
(    O
while    O
at    O
DDB    O
Needham    O
)    O
,    O
including    O
"    O
Menu    O
Chant    O
"    O
,    O
which    O
was    O
sung    O
by    O
,    O
among    O
others    O
,    O
Carl    O
Giammarese    O
of    O
The    O
Buckinghams    O
,    O
the    O
"    O
We    O
're    O
All    O
Connected    O
"    O
campaign    O
for    O
New    O
York    O
Telephone    O
(    O
while    O
at    O
Young    O
&    O
Rubicam    O
)    O
,    O
and    O
the    O
Lunesta    B-Piperazine103946814
Moth    O
campaign    O
(    O
while    O
at    O
McCann    O
Erickson    O
)    O
for    O
which    O
she    O
won    O
an    O
Effie    O
award    O
.    O

zopiclone    B-Piperazine103946814
(    O
depressant    O
z    O
-    O
drug    O
)    O
and    O
its    O
stereoisomer    O
eszopiclone    B-Piperazine103946814

Eszopiclone    B-Piperazine103946814
(    O
Lunesta    O
)    O

This    O
has    O
also    O
been    O
recorded    O
in    O
non    O
-    O
benzodiazapine    O
sedatives    O
or    O
"    O
z    O
-    O
drugs    O
"    O
which    O
act    O
on    O
the    O
same    O
set    O
of    O
receptors    O
;    O
such    O
as    O
zolpidem    O
(    O
also    O
known    O
as    O
Ambien    O
)    O
,    O
eszopiclone    B-Piperazine103946814
(    O
also    O
known    O
as    O
Lunesta    O
)    O
,    O
and    O
zopiclone    B-Piperazine103946814
(    O
also    O
known    O
by    O
brand    O
names    O
Imovane    O
and    O
Zimovane    O
)    O
.    O

3,4-Methylenedioxy-1-benzylpiperazine    B-Piperazine103946814
(    O
MDBZP    O
)    O

Other    O
cyclopyrrolone    O
drugs    O
include    O
zopiclone    B-Piperazine103946814
,    O
pagoclone    O
and    O
suriclone    B-Piperazine103946814
.    O

Ageusia    O
can    O
also    O
be    O
caused    O
by    O
medicinal    O
side    O
-    O
effects    O
from    O
antirheumatic    O
drugs    O
such    O
as    O
penicillamine    O
,    O
antiproliferative    O
drugs    O
such    O
as    O
cisplatin    O
,    O
ACE    O
inhibitors    O
,    O
and    O
other    O
drugs    O
including    O
azelastine    O
,    O
clarithromycin    O
,    O
terbinafine    O
,    O
and    O
zopiclone    B-Piperazine103946814
.    O

She    O
said    O
that    O
she    O
drank    O
to    O
escape    O
the    O
breakdown    O
of    O
her    O
relationship    O
with    O
Crane    O
,    O
later    O
revealing    O
she    O
also    O
had    O
an    O
addiction    O
to    O
Zopiclone    B-Piperazine103946814
sleeping    O
tablets    O
.    O

zopiclone    B-Piperazine103946814
(    O
depressant    O
z    O
-    O
drug    O
)    O
and    O
its    O
stereoisomer    O
eszopiclone    B-Piperazine103946814

Zopiclone    B-Piperazine103946814
(    O
Imovan    O
)    O

Many    O
drivers    O
had    O
blood    O
levels    O
far    O
exceeding    O
the    O
therapeutic    O
dose    O
range    O
,    O
suggesting    O
a    O
high    O
degree    O
of    O
abuse    O
potential    O
for    O
benzodiazepines    O
and    O
zolpidem    O
and    O
zopiclone    B-Piperazine103946814
.    O

This    O
has    O
also    O
been    O
recorded    O
in    O
non    O
-    O
benzodiazapine    O
sedatives    O
or    O
"    O
z    O
-    O
drugs    O
"    O
which    O
act    O
on    O
the    O
same    O
set    O
of    O
receptors    O
;    O
such    O
as    O
zolpidem    O
(    O
also    O
known    O
as    O
Ambien    O
)    O
,    O
eszopiclone    B-Piperazine103946814
(    O
also    O
known    O
as    O
Lunesta    O
)    O
,    O
and    O
zopiclone    B-Piperazine103946814
(    O
also    O
known    O
by    O
brand    O
names    O
Imovane    O
and    O
Zimovane    O
)    O
.    O

Telenzepine    B-Piperazine103946814
is    O
atropisomeric    O
,    O
in    O
other    O
words    O
the    O
molecule    O
has    O
a    O
stereogenic    O
C–    O

Since    O
its    O
introduction    O
in    O
November    O
2008    O
it    O
has    O
been    O
distributed    O
under    O
the    O
commercial    O
name    O
Masivet    B-Piperazine103946814
.    O

In    O
the    O
USA    O
it    O
was    O
distributed    O
under    O
the    O
name    O
Kinavet    B-Piperazine103946814
,    O
however    O
the    O
FDA    O
made    O
Kinavet    O
illegal    O
in    O
the    O
US    O
effective    O
December    O
2015    O
,    O
therefore    O
the    O
use    O
of    O
the    O
drug    O
is    O
no    O
longer    O
allowed    O
in    O
the    O
US    O
at    O
this    O
time    O
.    O

Umespirone    B-Piperazine103946814
-    O
anxiolytic    O

meta    O
"-    O
Chlorophenylpiperazine    O
("'mCPP    B-Piperazine103946814
)    O
is    O
a    O
psychoactive    O
drug    O
of    O
the    O
phenylpiperazine    B-Piperazine103946814
class    O
.    O

Trazodone    O
,    O
both    O
itself    O
and    O
via    O
its    O
major    O
active    O
metabolite    O
"meta"-chlorophenylpiperazine    B-Piperazine103946814
(    O
mCPP    O
)    O
,    O
also    O
binds    O
to    O
a    O
variety    O
of    O
other    O
receptors    O
.    O

The    O
drug    O
is    O
extensively    O
metabolized    O
,    O
with    O
three    O
or    O
four    O
major    O
metabolites    O
having    O
been    O
identified    O
in    O
the    O
human    O
body    O
,    O
particularly    O
mCPP    B-Piperazine103946814
,    O
which    O
may    O
contribute    O
to    O
the    O
side    O
effect    O
profile    O
of    O
trazodone    O
and    O
which    O
probably    O
accounts    O
for    O
trazodone    O
's    O
serotonergic    O
effects    O
.    O

Thiethylperazine    B-Piperazine103946814
(    O
Torecan    B-Piperazine103946814
)    O
is    O
an    O
antiemetic    O
of    O
the    O
phenothiazine    O
class    O
.    O

Many    O
drugs    O
that    O
contain    O
amines    O
are    O
provided    O
as    O
the    O
maleate    O
acid    O
salt    O
,    O
e.g.    O
carfenazine    O
,    O
chlorpheniramine    O
,    O
pyrilamine    O
,    O
methylergonovine    O
,    O
and    O
thiethylperazine    B-Piperazine103946814
.    O

Bifeprunox    B-Piperazine103946814
–    O
Antipsychotic    O

Other    O
drugs    O
related    O
to    O
hydroxyzine    O
are    O
cyclizine    B-Piperazine103946814
,    O
buclizine    B-Piperazine103946814
,    O
and    O
meclizine    B-Piperazine103946814
,    O
and    O
they    O
share    O
all    O
or    O
most    O
of    O
the    O
benefits    O
,    O
indications    O
,    O
contraindications    O
,    O
cautions    O
,    O
and    O
side    O
effects    O
of    O
hydroxyzine    O
.    O

Analogues    O
of    O
hydroxyzine    O
include    O
buclizine    B-Piperazine103946814
,    O
cetirizine    O
,    O
cinnarizine    B-Piperazine103946814
,    O
cyclizine    B-Piperazine103946814
,    O
etodroxizine    O
,    O
meclizine    B-Piperazine103946814
,    O
and    O
pipoxizine    O
among    O
others    O
.    O

:*    O
Vertipam    O
(    O
"    O
cyclizine    B-Piperazine103946814
,    O
diazepam    O
and    O
nicotinic    O
acid    O
"    O
)    O

However    O
,    O
it    O
is    O
noted    O
that    O
opioid    O
/    O
antihistamine    O
combinations    O
are    O
used    O
clinically    O
for    O
their    O
synergistic    O
effect    O
in    O
the    O
management    O
of    O
pain    O
and    O
maintenance    O
of    O
dissociative    O
anesthesia    O
(    O
sedation    O
)    O
in    O
such    O
preparations    O
as    O
Meprozine    O
(    O
meperidine    O
/    O
promethazine    O
)    O
and    O
Diconal    O
(    O
dipipanone    O
/    O
cyclizine    B-Piperazine103946814
)    O
,    O
which    O
act    O
as    O
strong    O
anticholinergic    O
agents    O
.    O

SB-271,046    B-Piperazine103946814

A    O
recent    O
study    O
has    O
shown    O
that    O
mixtures    O
of    O
BZP    O
with    O
other    O
piperazine    O
drugs    O
such    O
as    O
TFMPP    B-Piperazine103946814
share    O
certain    O
pharmacodynamic    O
traits    O
with    O
MDMA    O
.    O

3-Trifluoromethylphenylpiperazine    B-Piperazine103946814
(    O
TFMPP    O
)    O

TFMPP    B-Piperazine103946814

It    O
is    O
closely    O
related    O
to    O
several    O
other    O
piperazines    O
,    O
including    O
eltoprazine    O
and    O
batoprazine    B-Piperazine103946814
,    O
and    O
TFMPP    B-Piperazine103946814
,    O
as    O
well    O
as    O
more    O
distantly    O
to    O
the    O
azapirones    O
such    O
as    O
buspirone    O
.    O

It    O
is    O
also    O
a    O
known    O
precursor    O
to    O
S-15535    B-Piperazine103946814
&    O
Lecozotan    O
.    O

In    O
addition    O
to    O
the    O
naturally    O
occurring    O
ergonovine    O
(    O
used    O
as    O
an    O
oxytocic    O
)    O
and    O
ergotamine    O
(    O
a    O
vasoconstrictor    O
used    O
to    O
control    O
migraine    O
)    O
,    O
synthetic    O
derivatives    O
of    O
importance    O
are    O
the    O
oxytocic    O
methergine    O
,    O
the    O
anti    O
-    O
migraine    O
drugs    O
dihydroergotamine    B-Piperazine103946814
and    O
methysergide    O
,    O
hydergine    O
(    O
a    O
mixture    O
of    O
dihydroergotoxine    O
mesylates    O
,    O
INN    O
:    O
ergoline    O
mesylates    O
)    O
,    O
and    O
bromocriptine    O
,    O
used    O
for    O
numerous    O
purposes    O
including    O
treatment    O
of    O
Parkinson    O
's    O
disease    O
.    O

Dihydroergotamine    B-Piperazine103946814
,    O
a    O
semi    O
-    O
synthetic    O
form    O
used    O
as    O
an    O
abortive    O
migraine    O
treatment    O

Zolmitriptan    O
may    O
increase    O
blood    O
pressure    O
,    O
it    O
should    O
not    O
be    O
given    O
to    O
patients    O
with    O
uncontrolled    O
hypertension    O
,    O
should    O
not    O
be    O
used    O
within    O
24    O
hours    O
of    O
treatment    O
with    O
another    O
5-HT1    O
agonist    O
,    O
or    O
an    O
ergotamine    O
-    O
containing    O
or    O
ergot    O
-    O
type    O
medication    O
like    O
dihydroergotamine    B-Piperazine103946814
or    O
methysergide    O
,    O
and    O
should    O
not    O
be    O
administered    O
to    O
patients    O
with    O
hemiplegic    O
or    O
basilar    O
migraine    O
.    O

VX-680    B-Piperazine103946814
is    O
an    O
aurora    O
inhibitor    O
.    O

Opipramol    B-Piperazine103946814
,    O
sold    O
under    O
the    O
brand    O
name    O
Insidon    B-Piperazine103946814
among    O
others    O
,    O
is    O
an    O
anxiolytic    O
and    O
antidepressant    O
which    O
is    O
used    O
throughout    O
Europe    O
.    O

The    O
antidepressants    O
that    O
do    O
not    O
act    O
through    O
the    O
monoamine    O
system    O
,    O
such    O
as    O
tianeptine    O
and    O
opipramol    B-Piperazine103946814
,    O
have    O
been    O
known    O
for    O
a    O
long    O
time    O
.    O

Benzylfentanyl    B-Piperazine103946814

Niaprazine    B-Piperazine103946814
(    O
INN    O
)    O
(    O
brand    O
name    O
Nopron    B-Piperazine103946814
)    O
is    O
a    O
sedative    O
-    O
hypnotic    O
drug    O
of    O
the    O
phenylpiperazine    B-Piperazine103946814
group    O
.    O

Olanzapine    B-Piperazine103946814

Few    O
available    O
atypical    O
antipsychotics    O
are    O
known    O
to    O
possess    O
antidepressant    O
efficacy    O
in    O
bipolar    O
disorder    O
(    O
with    O
the    O
notable    O
exceptions    O
being    O
quetiapine    O
,    O
olanzapine    B-Piperazine103946814
and    O
possibly    O
asenapine    O
)    O
as    O
a    O
monotherapy    O
,    O
even    O
though    O
the    O
majority    O
of    O
atypical    O
antipsychotics    O
are    O
known    O
to    O
possess    O
significant    O
antimanic    O
activity    O
,    O
which    O
is    O
yet    O
to    O
be    O
clearly    O
demonstrated    O
for    O
lurasidone    O
.    O

In    O
animal    O
studies    O
,    O
it    O
reversed    O
dizocilpine    O
-    O
induced    O
learning    O
and    O
memory    O
impairment    O
and    O
was    O
found    O
to    O
be    O
superior    O
in    O
doing    O
this    O
to    O
all    O
of    O
the    O
other    O
antipsychotics    O
examined    O
,    O
including    O
risperidone    O
,    O
olanzapine    B-Piperazine103946814
,    O
quetiapine    O
,    O
clozapine    O
,    O
aripiprazole    B-Piperazine103946814
,    O
and    O
haloperidol    O
.    O

Olanzapine    B-Piperazine103946814

Olanzapine    B-Piperazine103946814

Olanzapine    B-Piperazine103946814

Olanzapine    B-Piperazine103946814

Olanzapine    B-Piperazine103946814

Its    O
use    O
in    O
intramuscular    O
sedation    O
has    O
been    O
replaced    O
by    O
intramuscular    O
preparations    O
of    O
haloperidol    O
,    O
midazolam    O
,    O
clonazepam    O
and    O
olanzapine    B-Piperazine103946814
.    O

Olanzapine    B-Piperazine103946814
(    O
Zyprexa    O
)    O

Olanzapine    B-Piperazine103946814
,    O
atypical    O
antipsychotic    O
and    O
mood    O
stabilizer    O

Olanzapine    B-Piperazine103946814
may    O
be    O
an    O
effective    O
monotherapy    O
in    O
psychotic    O
depression    O
,    O
although    O
there    O
is    O
evidence    O
that    O
it    O
is    O
ineffective    O
for    O
depressive    O
symptoms    O
as    O
a    O
monotherapy    O
;    O
and    O
olanzapine    O
/    O
fluoxetine    O
is    O
more    O
effective    O
.    O

Olanzapine    B-Piperazine103946814
/    O
sertraline    O

Some    O
antipsychotic    O
agents    O
may    O
be    O
more    O
risky    O
during    O
withdrawal    O
than    O
others    O
,    O
especially    O
clozapine    O
,    O
olanzapine    B-Piperazine103946814
or    O
low    O
potency    O
phenothiazines    O
(    O
e.g.    O
,    O
chlorpromazine    O
)    O
,    O
as    O
they    O
lower    O
the    O
seizure    O
threshold    O
and    O
can    O
worsen    O
withdrawal    O
effects    O
;    O
if    O
used    O
,    O
extreme    O
caution    O
is    O
required    O
.    O

This    O
is    O
a    O
list    O
of    O
adverse    O
effects    O
of    O
the    O
antipsychotic    O
olanzapine    B-Piperazine103946814
,    O
sorted    O
by    O
frequency    O
of    O
occurrence    O
.    O

Review    O
of    O
treatment    O
of    O
excoriation    O
disorder    O
have    O
shown    O
that    O
the    O
following    O
medications    O
may    O
be    O
effective    O
in    O
reducing    O
picking    O
behavior    O
:    O
doxepin    O
,    O
clomipramine    O
,    O
naltrexone    O
,    O
pimozide    O
,    O
and    O
olanzapine    B-Piperazine103946814
.    O

In    O
one    O
case    O
,    O
a    O
patient    O
had    O
not    O
been    O
responding    O
to    O
haloperidol    O
,    O
thus    O
the    O
physician    O
tried    O
olanzapine    B-Piperazine103946814
.    O

Olanzapine    B-Piperazine103946814

Quetiapine    O
,    O
sulpiride    O
and    O
olanzapine    B-Piperazine103946814
,    O
the    O
atypical    O
neuroleptic    O
agents    O
,    O
are    O
less    O
likely    O
to    O
yield    O
drug    O
-    O
induced    O
parkinsonism    O
and    O
tardive    O
dyskinesia    O

Olanzapine    B-Piperazine103946814

mitratapide    B-Piperazine103946814
(    O
USAN    O
)    O

mCPP    O
is    O
a    O
metabolite    O
of    O
a    O
variety    O
of    O
other    O
piperazine    O
drugs    O
including    O
trazodone    O
,    O
nefazodone    O
,    O
etoperidone    O
,    O
enpiprazole    B-Piperazine103946814
,    O
mepiprazole    O
,    O
cloperidone    O
,    O
and    O
peraclopone    O
.    O

LP-12    B-Piperazine103946814
(    O
4-(2-Diphenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide    O
)    O

Sonepiprazole    B-Piperazine103946814
—    O
dopaminergic    O

epsiprantel    B-Piperazine103946814
(    O
INN    O
)    O

Chlorcyclizine    B-Piperazine103946814
(    O
Di-Paralene    B-Piperazine103946814
,    O
Mantadil    B-Piperazine103946814
,    O
Pruresidine    B-Piperazine103946814
,    O
Trihistan    B-Piperazine103946814
)    O
is    O
a    O
first    O
-    O
generation    O
antihistamine    O
of    O
the    O
diphenylmethylpiperazine    B-Piperazine103946814
group    O
marketed    O
in    O
the    O
United    O
States    O
and    O
certain    O
other    O
countries    O
.    O

Vesnarinone    B-Piperazine103946814
–    O
Cardiotonic    O

Cefbuperazone    B-Piperazine103946814
(    O
INN    O
)    O
is    O
a    O
second    O
-    O
generation    O
cephalosporin    O
antibiotic    O
.    O

1,4-Dibenzylpiperazine    B-Piperazine103946814
(    O
DBZP    O
)    O

mazapertine    B-Piperazine103946814
(    O
INN    O
)    O

Ranbezolid    B-Piperazine103946814
(    O
RBx7644    O
)    O
is    O
an    O
oxazolidinone    O
antibacterial    O
.    O

Zicronapine    B-Piperazine103946814
(    O
,    O
previously    O
known    O
as    O
Lu    B-Piperazine103946814
31-130    I-Piperazine103946814
)    O
is    O
an    O
atypical    O
antipsychotic    O
medication    O
formerly    O
under    O
development    O
by    O
H.    O
Lundbeck    O
A    O
/    O
S.    O
In    O
phase    O
II    O
studies    O
zicronapine    O
showed    O
statistically    O
significant    O
separation    O
from    O
placebo    O
and    O
convincing    O
efficacy    O
and    O
safety    O
data    O
when    O
compared    O
to    O
olanzapine    B-Piperazine103946814
.    O

Nintedanib    B-Piperazine103946814
is    O
an    O
investigational    O
orally    O
-    O
administered    O
triple    O
angiokinase    O
inhibitor    O
that    O
targets    O
receptor    O
tyrosine    O
kinases    O
involved    O
in    O
the    O
regulation    O
of    O
angiogenesis    O
:    O
fibroblast    O
growth    O
factor    O
receptor    O
(    O
FGFR    O
)    O
,    O
platelet    O
-    O
derived    O
growth    O
factor    O
receptor    O
(    O
PDGFR    O
)    O
,    O
and    O
vascular    O
endothelial    O
growth    O
factor    O
receptor    O
(    O
VEGFR    O
)    O
,    O
which    O
have    O
also    O
been    O
implicated    O
in    O
the    O
pathogenesis    O
of    O
fibrosis    O
and    O
IPF    O
.    O

Sparfloxacin    B-Piperazine103946814

4-Trifluoromethylphenylpiperazine    B-Piperazine103946814
(    O
pTFMPP    O
)    O

Acetildenafil    B-Piperazine103946814
and    O
other    O
synthetic    O
structural    O
analogs    O
of    O
sildenafil    O
which    O
are    O
PDE5    O
inhibitors    O
have    O
been    O
found    O
as    O
adulterants    O
in    O
a    O
number    O
of    O
"    O
herbal    O
"    O
aphrodisiac    O
products    O
sold    O
over    O
-    O
the    O
-    O
counter    O
.    O

Commercially    O
available    O
organobromine    O
pharmaceuticals    O
include    O
the    O
vasodilator    O
nicergoline    O
,    O
the    O
sedative    O
brotizolam    O
,    O
the    O
anticancer    O
agent    O
pipobroman    B-Piperazine103946814
,    O
and    O
the    O
antiseptic    O
merbromin    O
.    O

7-Hydroxyamoxapine    B-Piperazine103946814
,    O
a    O
major    O
active    O
metabolite    O
of    O
amoxapine    O
,    O
is    O
a    O
more    O
potent    O
dopamine    O
receptor    O
antagonist    O
and    O
contributes    O
to    O
its    O
neuroleptic    O
efficacy    O
,    O
whereas    O
8-hydroxyamoxapine    O
is    O
a    O
norepinephrine    O
reuptake    O
inhibitor    O
but    O
a    O
stronger    O
serotonin    O
reuptake    O
inhibitor    O
and    O
helps    O
to    O
balance    O
amoxapine    O
's    O
ratio    O
of    O
serotonin    O
to    O
norepinephrine    O
transporter    O
blockade    O
.    O

Aripiprazole    B-Piperazine103946814

In    O
a    O
2013    O
meta    O
-    O
analysis    O
of    O
the    O
efficacy    O
and    O
tolerability    O
of    O
15    O
antipsychotic    O
drugs    O
it    O
was    O
found    O
to    O
produce    O
the    O
second    O
least    O
(    O
after    O
haloperidol    O
)    O
weight    O
gain    O
,    O
the    O
least    O
QT    O
interval    O
prolongation    O
,    O
the    O
fourth    O
"    O
most    O
"    O
extrapyramidal    O
side    O
effects    O
(    O
after    O
haloperidol    O
,    O
zotepine    O
and    O
chlorpromazine    O
)    O
and    O
the    O
sixth    O
least    O
sedation    O
(    O
after    O
paliperidone    O
,    O
sertindole    B-Piperazine103946814
,    O
amisulpride    O
,    O
iloperidone    O
and    O
aripiprazole    B-Piperazine103946814
)    O
.    O

In    O
animal    O
studies    O
,    O
it    O
reversed    O
dizocilpine    O
-    O
induced    O
learning    O
and    O
memory    O
impairment    O
and    O
was    O
found    O
to    O
be    O
superior    O
in    O
doing    O
this    O
to    O
all    O
of    O
the    O
other    O
antipsychotics    O
examined    O
,    O
including    O
risperidone    O
,    O
olanzapine    B-Piperazine103946814
,    O
quetiapine    O
,    O
clozapine    O
,    O
aripiprazole    B-Piperazine103946814
,    O
and    O
haloperidol    O
.    O

Aripiprazole    B-Piperazine103946814
(    O
atypical    O
antipsychotic    O
)    O

Aripiprazole    B-Piperazine103946814

Aripiprazole    B-Piperazine103946814

Aripiprazole    B-Piperazine103946814

Aripiprazole    B-Piperazine103946814
(    O
weak    O
partial    O
agonist    O
)    O

Aripiprazole    B-Piperazine103946814

Aripiprazole    B-Piperazine103946814
(    O
Abilify    O
)    O

Tends    O
to    O
produce    O
a    O
moderate    O
amount    O
of    O
sedation    O
,    O
less    O
than    O
clozapine    O
and    O
chlorpromazine    O
but    O
more    O
than    O
aripiprazole    B-Piperazine103946814
,    O
amisulpride    O
,    O
paliperidone    O
and    O
sertindole    B-Piperazine103946814
and    O
approximately    O
that    O
of    O
quetiapine    O
and    O
risperidone    O
.    O

He    O
was    O
among    O
the    O
first    O
to    O
demonstrate    O
co    O
-    O
transmission    O
in    O
the    O
1970s    O
and    O
also    O
played    O
a    O
pivotal    O
role    O
in    O
developing    O
the    O
atypical    O
antipsychotic    O
,    O
aripiprazole    B-Piperazine103946814
.    O

Aripiprazole    B-Piperazine103946814
(    O
weak    O
partial    O
agonist    O
)    O

Ponatinib    B-Piperazine103946814
(    O
Iclusig    O
)    O
by    O
Ariad    O
was    O
approved    O
in    O
2013    O
for    O
use    O
as    O
second    O
-    O
line    O
CML    O
treatment    O
,    O
and    O
is    O
the    O
only    O
licensed    O
TKI    O
which    O
binds    O
to    O
the    O
T315I    O
mutated    O
kinase    O
successfully    O
.    O

ARIAD    O
Pharmaceuticals    O
,    O
Inc.    O
announced    O
on    O
September    O
10    O
,    O
2010    O
that    O
ponatinib    B-Piperazine103946814
,    O
an    O
orally    O
active    O
Bcr    O
-    O
Abl    O
TKI    O
effective    O
against    O
the    O
T315I    O
mutation    O
had    O
been    O
approved    O
for    O
a    O
phase    O
II    O
clinical    O
trial    O
.    O

The    O
response    O
of    O
irradiated    O
animals    O
to    O
antimicrobial    O
therapy    O
can    O
be    O
unpredictable    O
,    O
as    O
was    O
evident    O
in    O
experimental    O
studies    O
where    O
metronidazole    O
and    O
pefloxacin    B-Piperazine103946814
therapies    O
were    O
detrimental    O
.    O

Tends    O
to    O
produce    O
a    O
moderate    O
amount    O
of    O
sedation    O
,    O
less    O
than    O
clozapine    O
and    O
chlorpromazine    O
but    O
more    O
than    O
aripiprazole    B-Piperazine103946814
,    O
amisulpride    O
,    O
paliperidone    O
and    O
sertindole    B-Piperazine103946814
and    O
approximately    O
that    O
of    O
quetiapine    O
and    O
risperidone    O
.    O

Sertindole    B-Piperazine103946814

difloxacin    B-Piperazine103946814
(    O
INN    O
)    O

SB-258,585    B-Piperazine103946814

For    O
example    O
,    O
mazapertine    B-Piperazine103946814
,    O
aripiprazole    B-Piperazine103946814
&    O
fluanisone    B-Piperazine103946814
.    O

LP-211    B-Piperazine103946814

"    O
Piperazine    O
:    O
"    O
GBR-12935    B-Piperazine103946814
,    O
GBR    B-Piperazine103946814
12909    I-Piperazine103946814
,    O
DBL-583    B-Piperazine103946814

GBR-12935    B-Piperazine103946814

grepafloxacin    B-Piperazine103946814
(    O
INN    O
)    O

Dihydroergocryptine    B-Piperazine103946814

Dihydroergocryptine    B-Piperazine103946814
(    O
DHEC    B-Piperazine103946814
,    O
trade    O
names    O
Almirid    B-Piperazine103946814
,    O
Cripar    B-Piperazine103946814
)    O
is    O
a    O
dopamine    O
agonist    O
of    O
the    O
ergoline    O
chemical    O
class    O
that    O
is    O
used    O
as    O
an    O
antiparkinson    O
agent    O
.    O

4-Chlorophenylpiperazine    B-Piperazine103946814
(    O
pCPP    O
)    O

JCCC    O
scientists    O
developed    O
palbociclib    B-Piperazine103946814
(    O
PD    O
0332991    O
)    O
,    O
a    O
breast    O
-    O
cancer    O
drug    O
that    O
was    O
in    O
phase    O
III    O
clinical    O
trials    O
as    O
of    O
2015    O
.    O

Palbociclib    B-Piperazine103946814
,    O
doubles    O
PFS    O
of    O
letrozole    O
alone    O

temafloxacin    B-Piperazine103946814
(    O
Omniflox    O
)    O

VUF-6002    B-Piperazine103946814
(    O
1-[(5-Chloro-1H    O
-    O
benzimidazol-2-yl)carbonyl]-4-methylpiperazine    O
)    O

MK-212    B-Piperazine103946814

SB-399,885    B-Piperazine103946814

The    O
Mazzotti    O
reaction    O
,    O
first    O
described    O
in    O
1948    O
,    O
is    O
a    O
symptom    O
complex    O
seen    O
in    O
patients    O
after    O
undergoing    O
treatment    O
of    O
onchocerciasis    O
with    O
the    O
medication    O
diethylcarbamazine    B-Piperazine103946814
(    O
DEC    O
)    O
.    O

He    O
writes    O
that    O
he    O
suffered    O
from    O
elephantiasis    O
but    O
that    O
it    O
was    O
controlled    O
with    O
the    O
drug    O
Hetrazan    B-Piperazine103946814
.    O

Diethylcarbamazine    B-Piperazine103946814
(    O
for    O
treatment    O
of    O
Lymphatic    O
filariasis    O
)    O

Furthermore    O
,    O
treatment    O
of    O
"    O
M.    O
perstans    O
"    O
is    O
challenging    O
because    O
the    O
most    O
antifilarial    O
drugs    O
,    O
such    O
as    O
ivermectin    O
,    O
diethylcarbamazine    B-Piperazine103946814
,    O
and    O
albendazole    O
are    O
not    O
effective    O
.    O

While    O
diethylcarbamazine    B-Piperazine103946814
(    O
DEC    O
)    O
is    O
the    O
most    O
common    O
drug    O
used    O
to    O
treat    O
"    O
M.    O
perstans    O
"    O
infection    O
,    O
it    O
is    O
often    O
ineffective    O
,    O
especially    O
with    O
the    O
administration    O
of    O
only    O
a    O
single    O
dose    O
.    O

Terconazole    B-Piperazine103946814
is    O
an    O
antifungal    O
drug    O
used    O
to    O
treat    O
vaginal    O
yeast    O
infection    O
.    O


